Speech in prodromal and symptomatic Huntington’s disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases
Introduction
Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by an expanded trinucleotide repeat (CAG) in the mutant IT15 huntingtin (Htt) gene (Duyao et al., 1993; Gusella et al., 1983). HD involves premature neuronal cell atrophy in the neostriatum as well as in the wider cortical regions of the brain (Delmaire et al., 2013; Imarisio et al., 2008). No treatment is currently available to delay onset or slow the progression of HD.
The autosomal dominant inheritance of HD allows predictive diagnostic testing, which provides an opportunity for valuable information to be gathered about the natural history of the disease. There is evidence suggesting subtle changes in cognitive and fine motor skills that precede the appearance of chorea in people with the HD gene expansion (i.e., in premanifest HD, or PreHD) (Bechtel et al., 2010; Biglan et al., 2009; Duff et al., 2010; Paulsen et al., 2008; Stout et al., 2011; Tabrizi et al., 2011). These clinical changes may appear more than a decade before the onset of more debilitating symptoms (Ross and Tabrizi, 2011; Tabrizi et al., 2011), at which point the diagnosis of HD is made.
HD is characterized by motor disorder, cognitive decline and psychiatric symptoms (McColgan and Tabrizi, 2018; Roos, 2010; van Duijn et al., 2014). In the context of impairment in both motor and cognitive systems, a breakdown in speech is anticipated given the involvement of these domains in speech production. Preliminary work in this space suggests subtle speech changes appear in PreHD (Kaploun et al., 2011).
There are efforts to develop disease-modifying therapies specifically targeting PreHD, with the understanding that patients may respond to treatment before HD pathology progresses. One of the challenges in preventive HD clinical trials is the lack of objective, sensitive and reliable biological markers to evaluate intervention efficacy (Andre et al., 2014; Mestre et al., 2009; Ross et al., 2014). Speech decline is one of the earliest indicators of disease onset, which suggests it is a potential marker of disease trajectory and/or treatment response (Vogel et al., 2012). However, relatively little is known about the speech phenotype of HD or how speech devolves over the course of the disease. The relationship between speech deficits and neurodegeneration is also unclear as imaging studies on speech functions in HD are rare (Skodda et al., 2016). Here we conducted a comprehensive review and meta-analysis of the literature on speech production in HD.
Section snippets
Search strategy
We searched the literature available in three databases – MEDLINE (Web of Knowledge), PubMed (United States Library of Medicine) and PsycINFO (Wolters Kluwer Ovid). Search terms for MEDLINE and PubMed databases included: (speech OR “speech production” OR “speech impairment*” OR “speech disorder*” OR “speech timing” OR “apraxia of speech” OR AOS OR apraxi* OR dyspraxi* OR anarthri* OR dysarthri* OR voice OR “voice disorder*” OR dysphoni* OR phonat*) AND (“Huntington’s disease” OR “Huntington
Results
The literature search yielded 288 studies with no additional records identified from their reference lists. Of these, 183 records remained after 105 duplicates were removed. A further 148 were excluded for not meeting inclusion criteria after reviewing abstracts and titles alone. The remaining 35 full-text articles were further reviewed for eligibility. Eighteen studies did not meet inclusion criteria, and an additional five papers were excluded for methodological reasons (see Table 3 – Reasons
Discussion
Subtle speech deficits can be detected prior to diagnosis of HD across the speech dimensions of articulation, phonation and prosody, as indicated by reduced speech agility, reduced vocal fold control and varied speech-timing. Articulation agility and speech rate appear to be the most promising speech markers in premanifest HD, however, a clear understanding of the speech tasks that differentiate the speech of people with PreHD and healthy individuals remains unclear. Identification of a
Conclusion
Speech deficits are detectable in the premanifest phase of HD using instrumental analysis, possibly due to subtle decline in motor speech and cognitive functions. Our review highlights the promise of speech as a biobehavioral marker of disease. Stronger evidence is needed to establish the sensitivity and reliability of speech markers in detecting pathophysiological changes in PreHD and evaluating the effectiveness of pharmacological therapy. Nonetheless, the non-invasive and easy to acquire
Author contribution
Jess Chan: extraction, analysis and interpretation of data, drafting the manuscript. Julie Stout: interpretation of data, critical revision of the manuscript for intellectual content. Adam Vogel: study concept and design, interpretation of data, revising the manuscript, study supervision.
Financial disclosures
Associate Professor Vogel is funded by National Health and Medical Research Council, Dementia Fellowship, Australia (#1135683).
Declaration of Competing Interest
Mrs Chan declares no competing financial interest.
Professor Stout declares no competing financial interest.
Associate Professor Vogel is the Chief Science Officer of Redenlab, a speech biomarker company.
Acknowledgements
We would like to express our gratitude to Associate Professor Graham Hepworth from Melbourne Statistical Consulting Platform, The University of Melbourne for his guidance on data analysis in this review paper.
References (80)
- et al.
Biomarker development for Huntington’s disease
Drug Discov. Today
(2014) - et al.
Acoustic analysis of speech timing in huntington′s disease
Brain Lang.
(1994) - et al.
A systematic linguistic profile of spontaneous narrative speech in pre-symptomatic and early stage Huntington’s disease
Cortex
(2018) Neurolinguistic features of spontaneous language production dissociate three forms of neurodegenerative disease: alzheimer’s, Huntington’s, and Parkinson’s
Brain Lang.
(1989)- et al.
Speech timing in parkinson’s and huntington’s disease
Brain Lang.
(1987) - et al.
Maximum phonation time in healthy older adults
J. Voice
(2011) - et al.
Productive syntax abilities in Huntington’s and Parkinson’s diseases
Brain Cogn.
(2001) - et al.
Clinical and anatomical correlates of apraxia of speech
Brain Lang.
(2006) - et al.
White matter connectivity reflects clinical and cognitive status in Huntington’s disease
Neurobiol. Dis.
(2014) - et al.
Huntington’s disease: from molecular pathogenesis to clinical treatment
Lancet Neurol.
(2011)
Gender-related patterns of dysprosody in Parkinson disease and correlation between speech variables and motor symptoms
J. Voice
Maximum phonation time: variability and reliability
J. Voice
Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis
Lancet Neurol.
Acoustic analysis of voice in Huntington’s disease patients
J. Voice
The impact of task automaticity on speech in noise
Speech Commun.
Speech acoustic markers of early stage and prodromal Huntington’s disease: a marker of disease onset?
Neuropsychologia
Articulatory-acoustic vowel space: application to clear speech in individuals with Parkinson’s disease
J. Commun. Disord.
Phonatory function of neurologically impaired patients
J. Commun. Disord.
Kinematic analysis of articulatory movments in central motor disorders
Mov. Disord.
Longitudinal change in regional brain volumes in prodromal Huntington disease
J. Neurol. Neurosurg. Psychiatry
Tapping linked to function and structure in premanifest and symptomatic Huntington disease
Neurology
Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study
Mov. Disord.
A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus
Hum. Brain Mapp.
Striatal degeneration impairs language learning: evidence from Huntington’s disease
Brain
The structural correlates of functional deficits in early huntington’s disease
Hum. Brain Mapp.
Mild cognitive impairment in prediagnosed Huntington disease
Neurology
Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington’s disease
Hum. Brain Mapp.
Trinucleotide repeat length instability and age of onset in Huntington’s disease
Nat. Genet.
A polymorphic DNA marker genetically linked to Huntington’s disease
Nature
Speech delay as a consistent early feature of juvenile Huntington’s disease
Neurology
Speech disorders in mild and moderate Huntington disease: results of dysarthria assessments of 19 individuals
J. Med. Speech Lang. Pathol.
Acoustic analysis of speech prosody in Huntington’s and Parkinson’s disease: a preliminary report
Clin. Linguist. Phon.
Measuring inconsistency in meta-analyses
Br. Med. J.
Speech impairment in a large sample of patients with Parkinson’s disease
Behav. Neurol.
Methods of Meta-analysis : Correcting Error and Bias in Research Findings
Huntington’s disease: from pathology and genetics to potential therapies
Biochem. J.
Dysphonia subsequent to severe traumatic brain injury: comparative perceptual, acoustic and electroglottographic analyses
Folia Phoniatr. Logop.
Respiratory decline is integral to disease progression in Huntington’s disease
Eur. Respir. J.
Acoustic analysis of voice and speech characteristics in presymptomatic gene carriers of Huntington’s disease: biomarkers for preclinical sign onset?
J. Med. Speech Lang. Pathol.
Toward an acoustic typology of motor speech disorders
Clin. Linguist. Phon.
Cited by (33)
Test-retest reliability of acoustic and linguistic measures of speech tasks
2023, Computer Speech and LanguageEmotion expression through spoken language in Huntington disease
2022, CortexCitation Excerpt :Speech can be filtered to make language unintelligible, but at the cost of information loss. Moreover, HD individuals suffer from voice impairments unrelated to emotions that easily distinguish them from controls (Chan et al., 2019; Perez et al., 2018; Riad et al., 2020; Rusz et al., 2014). Indeed, patients exhibit speech disorders that are not emotion-specific, such as dysarthria or speech initiation disorders (Chan et al., 2019; Ludlow et al., 1987; Rusz et al., 2014).
Discriminating speech traits of Alzheimer's disease assessed through a corpus of reading task for Spanish language
2022, Computer Speech and LanguageAdults with a history of recreational cannabis use have altered speech production
2021, Drug and Alcohol DependenceCitation Excerpt :For example, voice onset time, a measure of the transition between sounds in words, is altered in patients with Parkinson’s disease (e.g., Fischer and Goberman, 2010) or hypoxic brain damage (e.g., Cymerman et al., 2002). Stark differences in speech timing are also commonly reported in disorders with genesis in the cerebellum (e.g., Friedreich ataxia) (Rosen et al., 2012) and the striatum (e.g., Huntington’s disease) (Chan et al., 2019) as well as affective conditions (e.g., depression) (Mundt et al., 2012). The main limitation of the current study was inclusion of five subjects in the cannabis group that returned a positive urine screen for cannabis, however none reported use in the 12 h prior to the experiment.
Striatum and language processing: Where do we stand?
2021, CognitionCitation Excerpt :The speech of patients in the early stages of HD differs from that of healthy controls: they have speech initiation disorders with a longer delay producing words and display pauses between and within words, compared to controls (Ludlow, Connor, & Bassich, 1987; Vogel, Shirbin, Churchyard, & Stout, 2012). Even in carriers of the genetic mutation without overt motor manifestation (so-called premanifest participants, or preHD), speech is characterized by impaired agility, slowing down, and phonatory dysfunction (Chan, Stout, & Vogel, 2019; Riad et al., 2020; Rusz, Saft, Schlegel, Hoffman, & Skodda, 2014). In contrast, in PD, the inhibitory system is increased, leading to reduced movement with hypophonia associated with hypernasality (Novotný et al., 2016).
Plasticity of stereotyped birdsong driven by chronic manipulation of cortical-basal ganglia activity
2021, Current BiologyCitation Excerpt :Cortical-basal ganglia (CBG) circuits play a critical role in learning and performing complex motor sequences, including speech,1–3 and are a major site of pathology. Damage to or dysfunction of the basal ganglia is associated with speech problems that worsen with disease progression, such as imprecise articulation, abnormal timing of vocal onsets and offsets, changes in pitch range and loudness, and stuttering.4–6 Electrophysiological recordings in animal models and in patients with movement disorders have found that motor dysfunction is associated with abnormal firing patterns throughout the CBG circuit, such as increased burst firing, enhanced synchrony among neurons within a region, and oscillatory activity (reviewed in Rubin et al.7 and Wichmann8).